Quantitative metabolic 7T imaging of tumour microenvironments

Quantitative metabolic 7T imaging of tumour microenvironments - QTIME

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030626

Enrollment

Registered

2022-10-31

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71.9

Interventions

Group 1: Pilot study for new/improved imaging techniques - descriptive analysis of a patient cohort. Method development: 20 7T MRSI measurements (~1 hour) in healthy subjects and 10 MRSI measurements

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: informed consent; no contraindications for 7T MR imaging (claustrophobia, ferromagnetic metal implants, weight <30 kg); no pregnancy; no breast feeding; no recent head/brain surgery before the participation in this study.

Exclusion criteria

Exclusion criteria: contraindications for 7T MR imaging (claustrophobia, ferromagnetic metal implants, weight <30 kg); pregnancy; breast feeding; recent head/brain surgery before the participation in this study.

Design outcomes

Primary

Measure	Time frame
1- Establishing internal water reference based oncometabolite quantification for 7T MRSI We can implement robust and fast quantitative water imaging at 7T to determine local tissue water concentrations. These can be used as an internal water reference in heterogeneous tumour tissue for the voxel-wise estimation of metabolic concentrations in MRSI instead of metabolic ratios. 2- Intraoperative precision sampling of tumour microenvironments We can translate our quantitative onco-metabolite maps into ROIs for sampling of different TMEs. These ROIs can be transferred to neurosurgical navigation systems for an accurate sample extraction. A new interdepartmental workflow can be established to preserve, manage and transfer the acquired samples for molecular pathology and mass spectrometry analysis. 3- Mass spectrometry as gold standard for 7T MRSI An analysis of the obtained samples with state-of the art electrospray ionisation mass spectrometry (ESI-MS) can compare invasive and non-invasive determination of onco-metabolites. This gold standard will allow to evaluate MRSI fidelity for the definition of metabolic profiles for TMEs.	—

Measure

Time frame

1- Establishing internal water reference based oncometabolite quantification for 7T MRSI We can implement robust and fast quantitative water imaging at 7T to determine local tissue water concentrations. These can be used as an internal water reference in heterogeneous tumour tissue for the voxel-wise estimation of metabolic concentrations in MRSI instead of metabolic ratios. 2- Intraoperative precision sampling of tumour microenvironments We can translate our quantitative onco-metabolite maps into ROIs for sampling of different TMEs. These ROIs can be transferred to neurosurgical navigation systems for an accurate sample extraction. A new interdepartmental workflow can be established to preserve, manage and transfer the acquired samples for molecular pathology and mass spectrometry analysis. 3- Mass spectrometry as gold standard for 7T MRSI An analysis of the obtained samples with state-of the art electrospray ionisation mass spectrometry (ESI-MS) can compare invasive and non-invasive determination of onco-metabolites. This gold standard will allow to evaluate MRSI fidelity for the definition of metabolic profiles for TMEs.

—

Secondary

Measure	Time frame
see Primary Endpoint	—

Countries

Austria

Contacts

Public ContactGilbert Hangel

Medizinische Universität Wien - Exzellenzzentrum für Hochfeld-MR

gilbert.hangel@meduniwien.ac.at+4314040064710

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026